Revolution Medicines, Inc.
- RVMD
- NASDAQ
- Biotechnology
- Oncology (RAS-Mutant Cancers)
- Precision Cancer Therapies
- KRAS Inhibitors
$182.58
Today +2.60%Quote Oct 19, 2026, 05:00 PM UTC
−9.64%over the last month
Max drawdown −14.3%From 1-month high −14.3%3 months −1.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Revolution Medicines
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
883
Market value
$39.13B
Quote Oct 19
Floor
$176.74
3.2% below price
Resistance
$192.62
5.5% above price
Price vs analyst targets
24 analysts
Lowest target
$179.00Highest target
$320.00
$179.00Highest target
$320.00
- Price $182.58
- Average target $253.47
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 39% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RVMDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free